A GSK lab in London.
Oli Scarff | Getty Photographs
Britain’s GlaxoSmithKline and German biotech agency CureVac struck a 150 million euro ($180 million) deal to develop next-generation vaccines in opposition to Covid-19 that focus on a number of variants in a single product.
In a joint assertion on Wednesday, the companions mentioned they had been focusing on a potential launch in 2022.
GSK, which holds a stake in CureVac, will even assist the manufacturing of as much as 100 million doses of CureVac’s first era Covid-19 vaccine candidate in 2021, they mentioned.
For GSK, the world’s largest vaccine maker by gross sales, it marks a contemporary try and play a related function in combating the pandemic after a Covid-19 alliance with Sanofi was hobbled by improvement delays and after an identical collaboration with China’s Clover Biopharmaceuticals was ended.